Viatris (VTRS) Capital Expenditures (QoQ) (2021 - 2026)
Viatris (VTRS) Capital Expenditures (QoQ) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 32.33% |
| Mar 31, 2026 | -79.69% |
| Dec 31, 2025 | 126.38% |
| Sep 30, 2025 | 64.08% |
| Jun 30, 2025 | 24.18% |
| Mar 31, 2025 | -69.66% |
| Dec 31, 2024 | 82.34% |
| Sep 30, 2024 | 30.95% |
| Jun 30, 2024 | 18.07% |
| Mar 31, 2024 | -69.91% |
| Dec 31, 2023 | 72.58% |
| Sep 30, 2023 | 41.45% |
| Jun 30, 2023 | 41.84% |
| Mar 31, 2023 | -68.90% |
| Dec 31, 2022 | 47.93% |
| Sep 30, 2022 | 23.84% |
| Jun 30, 2022 | 30.08% |
| Mar 31, 2022 | -67.33% |
| Dec 31, 2021 | 63.14% |
| Sep 30, 2021 | 35.50% |